RT Journal Article
SR Electronic
T1 Glycoprotein Acetyls and Depression: testing for directionality and potential causality using longitudinal data and Mendelian randomization analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.06.22283149
DO 10.1101/2022.12.06.22283149
A1 Daisy C P Crick
A1 Eleanor Sanderson
A1 Hannah Jones
A1 Neil Goulding
A1 Maria Carolina Borges
A1 Gemma Clayton
A1 Alice R Carter
A1 Sarah Halligan
A1 Deborah A Lawlor
A1 Golam M Khandaker
A1 Abigail Fraser
YR 2022
UL http://medrxiv.org/content/early/2022/12/06/2022.12.06.22283149.abstract
AB Background Inflammation is implicated in depression, but the issue of causality remains unclear.Objectives To investigate potential causality and direction of effect between inflammation and depression.Methods Using data from the ALSPAC birth cohort (n=4021), we used multivariable regression to investigate bidirectional longitudinal associations of GlycA and depression symptoms score and diagnosis, assessed at ages 18y and 24y.We used two-sample Mendelian randomization (MR) to investigate potential causality and directionality. Genetic variants for GlycA were obtained from UK Biobank (UKBB) (N=115,078); for depression from the Psychiatric Genomics Consortium and UKBB (N=500,199); and for depressive symptoms (N=161,460) from the Social Science Genetic Association Consortium. In addition to the Inverse Variance Weighted (IVW) method, we used sensitivity analyses to strengthen causal inference. We conducted multivariable MR adjusting for body mass index (BMI) due to known genetic correlation between inflammation, depression and BMI.Results After adjusting for potential confounders we found no association between GlycA and depression symptoms score or vice versa. We observed an association between GlycA and depression diagnosis (OR=1.18, 95% CI: 1.03-1.36).MR suggested no causal effect of GlycA on depression, but there was evidence of a causal effect of depression on GlycA (mean difference in GlycA = 0.09; 95% CI: 0.03-0.16), which was maintained in some, but not all, sensitivity analyses.Conclusion We found no consistent evidence for an effect of the inflammatory marker GlycA on depression. There was some evidence that depression may increase GlycA, but this may be confounded/mediated by BMI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and DC will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This research was specifically funded by Wellcome Trust and MRC (core) (Grant ref: 76467/Z/05/Z); MRC (Grant ref: MR/L022206/1) and Wellcome Trust (Grant ref: 8426812/Z/07/Z). This work was supported in part by the GW4 BIOMED DTP (D.C. MR/N0137941/) awarded to the Universities of Bath Bristol Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. GMK acknowledges funding support from the Wellcome Trust (grant code: 201486/Z/16/Z) the MQ: Transforming Mental Health (grant code: MQDS17/40) the Medical Research Council UK (grant code: MC_PC_17213 and MR/S037675/1) and the BMA Foundation (J Moulton grant 2019). AF GK and others works in the MRC Integrative Epidemiology Unit (MC_UU_00011) ARC and MCB work in the MRC Integrative Epidemiology Unit (MC_UU_00011/6) and are supported by the University of Bristol British Heart Foundation Accelerator Award (AA/18/7/34219) The research by MCB was supported by a UK Medical Research Council (MRC) Skills Development Fellowship (MR/P014054/1) and a Vice-Chancellors Fellowship from the University of Bristol.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics and Law Committee and the Local Research Ethics Committee of ALSPAC gave Ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genetic data are available online at https://gwas.mrcieu.ac.uk/ The process of accessing ALSPAC data and samples in detail are provided on the ALSPAC website: https://www.bristol.ac.uk/alspac/researchers/access/